MY208408A - Process for the preparation of a medicament containing an oxepane ring - Google Patents
Process for the preparation of a medicament containing an oxepane ringInfo
- Publication number
- MY208408A MY208408A MYPI2022001035A MYPI2022001035A MY208408A MY 208408 A MY208408 A MY 208408A MY PI2022001035 A MYPI2022001035 A MY PI2022001035A MY PI2022001035 A MYPI2022001035 A MY PI2022001035A MY 208408 A MY208408 A MY 208408A
- Authority
- MY
- Malaysia
- Prior art keywords
- preparation
- medicament containing
- oxepane ring
- oxepane
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
A process for the manufacture N-(5-((5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl- 1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide (I) is claimed. [NO SUITABLE FIGURE]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898861P | 2019-09-11 | 2019-09-11 | |
| US201962934382P | 2019-11-12 | 2019-11-12 | |
| PCT/US2020/050086 WO2021050654A1 (en) | 2019-09-11 | 2020-09-10 | Process for the preparation of a medicament containing an oxepane ring. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY208408A true MY208408A (en) | 2025-05-08 |
Family
ID=72614037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022001035A MY208408A (en) | 2019-09-11 | 2020-09-10 | Process for the preparation of a medicament containing an oxepane ring |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11414412B2 (en) |
| EP (1) | EP4028396B1 (en) |
| JP (1) | JP7370457B2 (en) |
| KR (1) | KR102786186B1 (en) |
| CN (1) | CN114341134B (en) |
| AU (1) | AU2020345916B2 (en) |
| BR (1) | BR112022004455B1 (en) |
| CA (1) | CA3147844A1 (en) |
| CL (1) | CL2022000581A1 (en) |
| CR (1) | CR20220100A (en) |
| ES (1) | ES2972049T3 (en) |
| IL (1) | IL291174B2 (en) |
| MX (1) | MX2022002962A (en) |
| MY (1) | MY208408A (en) |
| PE (1) | PE20220709A1 (en) |
| PL (1) | PL4028396T3 (en) |
| SA (1) | SA522431923B1 (en) |
| TW (1) | TWI856177B (en) |
| WO (1) | WO2021050654A1 (en) |
| ZA (1) | ZA202202178B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130296569A1 (en) * | 2010-11-03 | 2013-11-07 | Vijaykumar Jagdishwar Patil | Process for the preparation of phosphoric acid mono-(1--4-methoxymethyl-piperidin-4-yl) ester |
| WO2014048939A1 (en) | 2012-09-26 | 2014-04-03 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| MX2016012007A (en) * | 2014-03-18 | 2016-12-05 | Hoffmann La Roche | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. |
| SE540295C2 (en) * | 2016-12-05 | 2018-05-29 | Glactone Pharma Dev Ab | Sulfonamide analogues of galiellalactone |
-
2020
- 2020-09-09 TW TW109130966A patent/TWI856177B/en active
- 2020-09-10 MX MX2022002962A patent/MX2022002962A/en unknown
- 2020-09-10 US US17/016,900 patent/US11414412B2/en active Active
- 2020-09-10 KR KR1020227008173A patent/KR102786186B1/en active Active
- 2020-09-10 AU AU2020345916A patent/AU2020345916B2/en active Active
- 2020-09-10 CA CA3147844A patent/CA3147844A1/en active Pending
- 2020-09-10 CN CN202080062691.1A patent/CN114341134B/en active Active
- 2020-09-10 MY MYPI2022001035A patent/MY208408A/en unknown
- 2020-09-10 IL IL291174A patent/IL291174B2/en unknown
- 2020-09-10 ES ES20776038T patent/ES2972049T3/en active Active
- 2020-09-10 CR CR20220100A patent/CR20220100A/en unknown
- 2020-09-10 PE PE2022000381A patent/PE20220709A1/en unknown
- 2020-09-10 JP JP2022515639A patent/JP7370457B2/en active Active
- 2020-09-10 BR BR112022004455-0A patent/BR112022004455B1/en active IP Right Grant
- 2020-09-10 PL PL20776038.0T patent/PL4028396T3/en unknown
- 2020-09-10 WO PCT/US2020/050086 patent/WO2021050654A1/en not_active Ceased
- 2020-09-10 EP EP20776038.0A patent/EP4028396B1/en active Active
-
2022
- 2022-02-21 ZA ZA2022/02178A patent/ZA202202178B/en unknown
- 2022-03-09 CL CL2022000581A patent/CL2022000581A1/en unknown
- 2022-03-10 SA SA522431923A patent/SA522431923B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI856177B (en) | 2024-09-21 |
| SA522431923B1 (en) | 2024-04-15 |
| CN114341134B (en) | 2024-03-08 |
| ES2972049T3 (en) | 2024-06-10 |
| EP4028396A1 (en) | 2022-07-20 |
| CN114341134A (en) | 2022-04-12 |
| IL291174B2 (en) | 2025-04-01 |
| JP7370457B2 (en) | 2023-10-27 |
| EP4028396B1 (en) | 2024-01-03 |
| AU2020345916B2 (en) | 2026-08-13 |
| US11414412B2 (en) | 2022-08-16 |
| PL4028396T3 (en) | 2024-04-29 |
| JP2022547536A (en) | 2022-11-14 |
| TW202116309A (en) | 2021-05-01 |
| CL2022000581A1 (en) | 2022-10-07 |
| CR20220100A (en) | 2022-05-23 |
| US20210070749A1 (en) | 2021-03-11 |
| BR112022004455B1 (en) | 2024-04-30 |
| BR112022004455A2 (en) | 2022-06-14 |
| KR102786186B1 (en) | 2025-03-27 |
| IL291174A (en) | 2022-05-01 |
| EP4028396C0 (en) | 2024-01-03 |
| CA3147844A1 (en) | 2021-03-18 |
| MX2022002962A (en) | 2022-09-29 |
| PE20220709A1 (en) | 2022-05-04 |
| WO2021050654A1 (en) | 2021-03-18 |
| IL291174B1 (en) | 2024-12-01 |
| AU2020345916A1 (en) | 2022-03-03 |
| ZA202202178B (en) | 2024-06-26 |
| KR20220047324A (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| WO2021250468A8 (en) | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | |
| GEAP202415804A (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| WO2014188178A9 (en) | Polymyxin derivatives and their use in combination therapy together with different antibiotics | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| WO2017035353A8 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
| EP4516353A3 (en) | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide | |
| SG10201907576SA (en) | Salts of pi3k inhibitor and processes for their preparation | |
| GEP20257772B (en) | Pyrrole compounds | |
| WO2019178191A8 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| GEP20217327B (en) | Spirocycle compounds and methods of making and using same | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| PH12021552263A1 (en) | Macrocyclic compounds as sting agonists | |
| PH12020550756A1 (en) | An agent for treating nocturnal pollakiuria | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2024007059A (en) | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease. | |
| IL276311B2 (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| CA3156320A1 (en) | 2-azaspiro[3.4]octane derivatives as m4 agonists | |
| WO2008133128A1 (en) | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes | |
| PH12021550788A1 (en) | New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| ZA202202178B (en) | Process for the preparation of a medicament containing an oxepane ring | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor | |
| EP4286007A3 (en) | Pharmaceutical formulation | |
| PH12022550860A1 (en) | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists | |
| EP4335515A3 (en) | Crystal forms of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)- 2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1 -yl]acetamide |